title: Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
abstract: There is still no consensus on the best approach for the treatment of relapsing acute promyelocytic leukemia. All-trans retinoic acid plus chemotherapy is hampered by potential mechanisms of resistance, and the safety profile of chemotherapy may be considered as not acceptable before stem cell transplantation. Arsenic trioxide provides an option for these patients.
authors.forename: Xavier
authors.initials: X
authors.lastname: Thomas
authors.forename: Arnaud
authors.initials: A
authors.lastname: Pigneux
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Raffoux
authors.forename: Francoise
authors.initials: F
authors.lastname: Huguet
authors.forename: Denis
authors.initials: D
authors.lastname: Caillot
authors.forename: Pierre
authors.initials: P
authors.lastname: Fenaux
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000628:therapy; D008875:Middle Aged; D010087:Oxides / Q000627:therapeutic use*; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use
chemical_list: D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide